Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bayer Sues Glenmark Over Patent for Rosacea Drug Finacea

A unit of Bayer AG, Germany’s largest drugmaker, sued India’s Glenmark Generics Ltd. seeking to stop sales of a generic form of its Finacea gel used to treat rosacea.

Glenmark, based in Mumbai, is seeking U.S. Food and Drug Administration approval for a generic version of the drug before Bayer’s patent expires in 2018, according to a complaint filed yesterday in federal court in Wilmington, Delaware.

Plaintiffs will suffer “irreparable harm for which they have no adequate remedy at law” unless Glenmark is prohibited from using the technology before the patent expires, Bayer said in court papers.

“Based on available information, Glenmark believes it may be a first applicant” to file for the generic version of Finacea “and may be entitled to 180 days of generic market exclusivity,” Glenmark said in a statement today.

Finacea had U.S. sales of about $95 million for the 12 months ending Sept. 30, according to data compiled by IMS Health, a provider of health-care information, Glenmark said.

The case is Intendis GMBH v. Glenmark Generics Ltd., 13-cv-00421, U.S. District Court, District of Delaware (Wilmington).

To see the patent, click: 6,534,070.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.